Enanta Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2836 www.enanta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Jun 11th, 2025 10:34 am
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - May 27th, 2025 5:00 am
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - May 22nd, 2025 5:00 am
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - May 15th, 2025 7:55 am
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - May 15th, 2025 5:39 am
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - May 12th, 2025 3:10 pm
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - May 12th, 2025 2:10 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - May 12th, 2025 2:01 pm
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates - May 8th, 2025 4:20 pm
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - May 5th, 2025 3:53 pm
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Apr 8th, 2025 5:00 am
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Mar 17th, 2025 5:00 am
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium - Mar 12th, 2025 5:00 am
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Feb 15th, 2025 5:21 am
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Feb 15th, 2025 5:14 am
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - Feb 14th, 2025 10:00 am
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Feb 10th, 2025 3:10 pm
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - Feb 10th, 2025 2:11 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 - Feb 10th, 2025 2:01 pm
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Jan 30th, 2025 6:03 am